Indication
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.
Medicine details
- Medicine name:
- cladribine (Mavenclad)
- SMC ID:
- SMC2751
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 03 March 2025